Enanta Pharmaceuticals (NASDAQ:ENTA) Issues Earnings Results

Enanta Pharmaceuticals (NASDAQ:ENTA) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.01, FiscalAI reports. Enanta Pharmaceuticals had a negative return on equity of 68.72% and a negative net margin of 89.56%.The company had revenue of $17.16 million during the quarter, compared to analyst estimates of $17.03 million.

Enanta Pharmaceuticals Price Performance

Shares of Enanta Pharmaceuticals stock traded down $0.34 during trading on Wednesday, hitting $14.19. The stock had a trading volume of 62,589 shares, compared to its average volume of 185,607. The firm has a market cap of $411.85 million, a P/E ratio of -5.45 and a beta of 1.01. The business has a fifty day moving average of $13.65 and a two-hundred day moving average of $13.51. Enanta Pharmaceuticals has a fifty-two week low of $5.03 and a fifty-two week high of $17.15.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Deutsche Bank AG increased its position in Enanta Pharmaceuticals by 4.6% in the 4th quarter. Deutsche Bank AG now owns 24,107 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 1,055 shares during the last quarter. Public Employees Retirement System of Ohio increased its position in Enanta Pharmaceuticals by 8.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 1,100 shares during the last quarter. Ameriprise Financial Inc. increased its position in Enanta Pharmaceuticals by 8.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 1,383 shares during the last quarter. Russell Investments Group Ltd. increased its position in Enanta Pharmaceuticals by 13.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock worth $197,000 after purchasing an additional 1,940 shares during the last quarter. Finally, Meeder Asset Management Inc. acquired a new position in Enanta Pharmaceuticals in the 4th quarter worth about $32,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ENTA has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Monday, April 20th. Rodman & Renshaw initiated coverage on Enanta Pharmaceuticals in a research report on Thursday, March 26th. They set a “buy” rating and a $20.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $20.29.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.